Clinical Trial

Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate CHIKV VLP booster vaccine induced serum neutralizing antibody (SNA) response at 3 or 4 years post-initial CHIKV VLP vaccination.
Protocol Amendment History 4 changes
notable Enrollment reduced: 800 -> 715 participants 2026-08-08
minor Trial arms changed: 7 -> 6 2026-08-08
notable Primary completion moved earlier: 2028-04 -> 2028-02 2026-08-08
minor Completion moved earlier: 2028-08 -> 2028-02 2026-08-08
Trial Details
NCT Number NCT06007183
Lead Sponsor Bavarian Nordic
Conditions Chikungunya Virus Infection
Enrollment 715 participants
Start Date 2023-08-30
Primary Completion 2028-02 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-07